Edition:
United States

Deena Beasley

Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva

Oct 17 2018

LOS ANGELES Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly and Amgen Inc, but exclude a rival medication from Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers.

U.S. regulator approves Teva migraine drug, shares rise

Sep 14 2018

Shares of Israeli drugmaker Teva Pharmaceutical Industries rose over 5 percent in after-hours trading on Friday after the U.S. Food and Drug Administration (FDA) approved the company's new migraine treatment, a drug Teva has been banking on to help revive its fortunes.

Oklahoma Medicaid tests new tactic to curb U.S. drug costs

Aug 23 2018

LOS ANGELES A new front in the battle over the cost of expensive medicines in the United States is opening up in Oklahoma, the first state where the government's Medicaid program is negotiating contracts for prescription drugs based on how well they work.

Express Scripts staking out million dollar gene therapies

Aug 15 2018

Express Scripts Holding Co built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.

RPT-FOCUS-Express Scripts staking out million dollar gene therapies

Aug 15 2018

Aug 15 Express Scripts Holding Co built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.

Express Scripts staking out million-dollar gene therapies

Aug 15 2018

Express Scripts Holding Co built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.

Eisai/Biogen to advance Alzheimer's drug, provide fresh hope

Aug 03 2018

(In this July 24th story, corrects paragraphs 3 and 16 to clarify that Eisai executive said the trial generated positive, rather than effective, results at lower doses)

Amgen's new migraine drug hits insurance hurdles

Jul 26 2018

Amgen Inc's push to get patients on its new $575 a month migraine drug before competition emerges in September is facing barriers from insurers.

World News